Predictive value of morphological features and proliferative markers (mitotic index, Ki-67, PHH3) in bronchopulmonary neuroendocrine tumors

Authors

DOI:

https://doi.org/10.14739/2310-1237.2021.3.239530

Keywords:

lung neuroendocrine tumor, morphology, mitotic index, necrosis, Ki-67, PHH3, metastases, survival rates, immunohistochemistry

Abstract

The aim of this study was to evaluate relations of mitotic index (MI), necrosis, IHC proliferative markers Ki-67 and PHH3, and their predictive value for lung neuroendocrine tumors (NETs) aggressiveness.

Materials and methods. The study used surgical and biopsy material from 64 patients with lung NETs before chemotherapy prescribing. Morphological study and IHC was performed. MI, necrosis, Ki-67 and PHH3 expression and metastatic disease and survival were estimated using nonparametric statistics.

Results. Statistically significant association of necrosis severity and survival rates was found (P = 0.021). This was true for comparing patients with no necrosis in tumor tissue and extensive foci of necrosis (P = 0.023). MI appeared to be associated with metastases in lymph nodes (P = 0.003) and with distant metastatic lesions (P = 0.029). Significant, direct association of Ki-67 and MI (P < 0.001), MI and PHH3 expression (P < 0.001) was found. However, there was no significant link between Ki-67 and PHH3 rates (P = 0.240). Ki-67 didn’t show any significant association with necrosis and metastases. Also, Ki-67 rates didn’t affect the patient survival. Data on PHH3 expression and their estimation appeared to be rather contradictory. PHH3 expression rates were lower than expected and did not exceed neither Ki-67 rates, nor MI.

Conclusions. MI and necrosis are reliable markers for the assessment of lung NETs aggressiveness. MI is statistically associated with metastatic lesion, while extensive necrosis – with survival rates. Ki-67 expression was significantly associated with MI. No significant association of Ki-67 and PHH3 expression, tumor’s morphological features, disease progression and prognosis was found. Contrary to our expectations, PHH3 showed no diagnostic and prognostic value in lung NETs.

Author Biographies

L. M. Zakhartseva, Bogomolets National Medical University; Kyiv City Clinical Oncological Center, Ukraine

MD, PhD, DSc, Professor of the Department of Pathological Anatomy

H. Ye. Chytaieva, Bogomolets National Medical University, Kyiv, Ukraine

Assistant of the Department of Pathological Anatomy

References

  1. Basuroy, R., Bouvier, C., Ramage, J. K., Sissons, M., & Srirajaskanthan, R. (2018). Delays and routes to diagnosis of neuroendocrine tumours. BMC cancer, 18(1), 1122. https://doi.org/10.1186/s12885-018-5057-3
  2. Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017). Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia, 19(12), 991-1002. https://doi.org/10.1016/j.neo.2017.09.002
  3. Riihimäki, M., Hemminki, A., Sundquist, K., Sundquist, J., & Hemminki, K. (2016). The epidemiology of metastases in neuroendocrine tumors. International journal of cancer, 139(12), 2679-2686. https://doi.org/10.1002/ijc.30400
  4. Hung Y. P. (2019). Neuroendocrine Tumors of the Lung: Updates and Diagnostic Pitfalls. Surgical pathology clinics, 12(4), 1055-1071. https://doi.org/10.1016/j.path.2019.08.012
  5. Melosky B. (2017). Low Grade Neuroendocrine Tumors of the Lung. Frontiers in oncology, 7, 119. https://doi.org/10.3389/fonc.2017.00119
  6. Ichiki, Y., Matsumiya, H., Mori, M., Kanayama, M., Nabe, Y., Taira, A., Shinohara, S., Kuwata, T., Takenaka, M., Hirai, A., Imanishi, N., Yoneda, K., Noguchi, H., Shimajiri, S., Fujino, Y., Nakayama, T., & Tanaka, F. (2018). Predictive factors of postoperative survival among patients with pulmonary neuroendocrine tumor. Journal of thoracic disease, 10(12), 6912-6920. https://doi.org/10.21037/jtd.2018.11.115
  7. Hendifar, A. E., Marchevsky, A. M., & Tuli, R. (2017). Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. Journal of thoracic oncology, 12(3), 425-436. https://doi.org/10.1016/j.jtho.2016.11.2222
  8. Righi, L., Gatti, G., Volante, M., & Papotti, M. (2017). Lung neuroendocrine tumors: pathological characteristics. Journal of thoracic disease, 9(Suppl 15), S1442-S1447. https://doi.org/10.21037/jtd.2017.01.59
  9. Derks, J. L., Speel, E. J., Thunnissen, E., van Suylen, R. J., Buikhuisen, W. A., van Velthuysen, M. L., & Dingemans, A. M. (2016). Neuroendocrine Cancer of the Lung: A Diagnostic Puzzle. Journal of thoracic oncology, 11(3), e35-e38. https://doi.org/10.1016/j.jtho.2015.10.013
  10. Hilal T. (2017). Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Therapeutic advances in medical oncology, 9(3), 189-199. https://doi.org/10.1177/1758834016678149
  11. Filosso, P. L., Falcoz, P. E., Solidoro, P., Pellicano, D., Passani, S., Guerrera, F., Ruffini, E., & ESTS Lung Neuroendocrine Working-Group Participating Centers* (2018). The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database. Journal of thoracic disease, 10(Suppl 29), S3528-S3532. https://doi.org/10.21037/jtd.2018.04.104
  12. La Rosa, S., & Uccella, S. (2021). Classification of neuroendocrine neoplasms: lights and shadows. Reviews in endocrine & metabolic disorders, 22(3), 527-538. https://doi.org/10.1007/s11154-020-09612-2
  13. Swinson, D. E., Jones, J. L., Richardson, D., Cox, G., Edwards, J. G., & O'Byrne, K. J. (2002). Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung cancer, 37(3), 235-240. https://doi.org/10.1016/s0169-5002(02)00172-1
  14. Sugimoto, A., Umemura, S., Miyoshi, T., Nakai, T., Kuroe, T., Nosaki, K., Ikeda, T., Udagawa, H., Kirita, K., Zenke, Y., Matsumoto, S., Yoh, K., Niho, S., Tsuboi, M., Goto, K., & Ishii, G. (2021). High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung. Lung cancer, 157, 1-8. https://doi.org/10.1016/j.lungcan.2021.05.018
  15. Rindi, G., & Inzani, F. (2020). Neuroendocrine neoplasm update: toward universal nomenclature. Endocrine-related cancer, 27(6), R211-R218. https://doi.org/10.1530/ERC-20-0036
  16. Bellizzi A. M. (2020). Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?. Human pathology, 96, 8-33. https://doi.org/10.1016/j.humpath.2019.12.002
  17. Pelosi, G., Sonzogni, A., Harari, S., Albini, A., Bresaola, E., Marchiò, C., Massa, F., Righi, L., Gatti, G., Papanikolaou, N., Vijayvergia, N., Calabrese, F., & Papotti, M. (2017). Classification of pulmonary neuroendocrine tumors: new insights. Translational lung cancer research, 6(5), 513-529. https://doi.org/10.21037/tlcr.2017.09.04
  18. Raphael, M. J., Chan, D. L., Law, C., & Singh, S. (2017). Principles of diagnosis and management of neuroendocrine tumours. CMAJ, 189(10), E398-E404. https://doi.org/10.1503/cmaj.160771
  19. Chirieac L. R. (2016). Tumor cell proliferation, proliferative index and mitotic count in lung cancer. Translational lung cancer research, 5(5), 554-556. https://doi.org/10.21037/tlcr.2016.10.10
  20. Rekhtman, N., Desmeules, P., Litvak, A. M., Pietanza, M. C., Santos-Zabala, M. L., Ni, A., Montecalvo, J., Chang, J. C., Beras, A., Preeshagul, I. R., Sabari, J. K., Rudin, C. M., Ladanyi, M., Klimstra, D. S., Travis, W. D., & Lai, W. C. (2019). Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Modern pathology, 32(8), 1106-1122. https://doi.org/10.1038/s41379-019-0248-2
  21. Joseph, M. G., Shibani, A., Panjwani, N., Arab, A., Shepherd, J., Stitt, L. W., & Inculet, R. (2015). Usefulness of Ki-67, Mitoses, and Tumor Size for Predicting Metastasis in Carcinoid Tumors of the Lung: A Study of 48 Cases at a Tertiary Care Centre in Canada. Lung cancer international, 2015, 545601. https://doi.org/10.1155/2015/545601
  22. Ha, S. Y., Choi, M., Lee, T., & Park, C. K. (2016). The Prognostic Role of Mitotic Index in Hepatocellular Carcinoma Patients after Curative Hepatectomy. Cancer research and treatment, 48(1), 180-189. https://doi.org/10.4143/crt.2014.321
  23. Ozturk Sari, S., Taskin, O. C., Gundogdu, G., Yegen, G., Onder, S., Keskin, M., Saglam, S., Ozluk, Y., Gulluoglu, M., & Mete, O. (2016). The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors. Endocrine pathology, 27(2), 162-170. https://doi.org/10.1007/s12022-016-9424-9
  24. Voss, S. M., Riley, M. P., Lokhandwala, P. M., Wang, M., & Yang, Z. (2015). Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas. The American journal of surgical pathology, 39(1), 13-24. https://doi.org/10.1097/PAS.0000000000000341
  25. Mirzaiian, E., Tabatabaei Ghods, Z. S., Tavangar, S. M., Emami, B., Oraie, M., Safyari, R., & Saffar, H. (2020). Utility of PHH3 in Evaluation of Mitotic Index in Breast Carcinoma and Impact on Tumor Grade. Asian Pacific journal of cancer prevention : APJCP, 21(1), 63-66. https://doi.org/10.31557/APJCP.2020.21.1.63
  26. Tsuta, K., Liu, D. C., Kalhor, N., Wistuba, I. I., & Moran, C. A. (2011). Using the mitosis-specific marker anti-phosphohistone H3 to assess mitosis in pulmonary neuroendocrine carcinomas. American journal of clinical pathology, 136(2), 252-259. https://doi.org/10.1309/AJCPDXFOPXGEF0RP
  27. Chan, D. L., Clarke, S. J., Diakos, C. I., Roach, P. J., Bailey, D. L., Singh, S., & Pavlakis, N. (2017). Prognostic and predictive biomarkers in neuroendocrine tumours. Critical reviews in oncology/hematology, 113, 268-282. https://doi.org/10.1016/j.critrevonc.2017.03.017
  28. Elmaci, İ., Altinoz, M. A., Sari, R., & Bolukbasi, F. H. (2018). Phosphorylated Histone H3 (PHH3) as a Novel Cell Proliferation Marker and Prognosticator for Meningeal Tumors: A Short Review. Applied immunohistochemistry & molecular morphology : AIMM, 26(9), 627-631. https://doi.org/10.1097/PAI.0000000000000499
  29. Laflamme, P., Mansoori, B. K., Sazanova, O., Orain, M., Couture, C., Simard, S., Trahan, S., Manem, V., & Joubert, P. (2020). Phospho-histone-H3 immunostaining for pulmonary carcinoids: impact on clinical appraisal, interobserver correlation, and diagnostic processing efficiency. Human pathology, 106, 74-81. https://doi.org/10.1016/j.humpath.2020.09.009
  30. Garg, R., Bal, A., DAS, A., Singh, N., & Singh, H. (2019). Proliferation Marker (Ki67) in Sub-Categorization of Neuroendocrine Tumours of the Lung. Proliferation Marker (Ki67) in Sub-Categorization of Neuroendocrine Tumours of the Lung. Turk patoloji dergisi, 35(1), 15-21. https://doi.org/10.5146/tjpath.2018.01436
  31. Elmaci, İ., Altinoz, M. A., Bolukbasi, F. H., Yapicier, O., & Sav, A. (2017). Paradoxical results obtained with Ki67-labeling and PHH3-mitosis index in glial tumors: a literature analysis. Clinical neuropathology, 36(6), 272-282. https://doi.org/10.5414/NP301028
  32. Metovic, J., Barella, M., Bianchi, F., Hofman, P., Hofman, V., Remmelink, M., Kern, I., Carvalho, L., Pattini, L., Sonzogni, A., Veronesi, G., Harari, S., Forest, F., Papotti, M., & Pelosi, G. (2021). Morphologic and molecular classification of lung neuroendocrine neoplasms. Virchows Archiv, 478(1), 5-19. https://doi.org/10.1007/s00428-020-03015-z
  33. Pelosi, G., Massa, F., Gatti, G., Righi, L., Volante, M., Birocco, N., Maisonneuve, P., Sonzogni, A., Harari, S., Albini, A., & Papotti, M. (2019). Ki-67 Evaluation for Clinical Decision in Metastatic Lung Carcinoids: A Proof of Concept. Clinical pathology, 12, 2632010X19829259. https://doi.org/10.1177/2632010X19829259
  34. Warth, A., Fink, L., Fisseler-Eckhoff, A., Jonigk, D., Keller, M., Ott, G., Rieker, R. J., Sinn, P., Söder, S., Soltermann, A., Willenbrock, K., Weichert, W., & Pulmonary Pathology Working Group of the German Society of Pathology (2013). Interobserver agreement of proliferation index (Ki-67) outperforms mitotic count in pulmonary carcinoids. Virchows Archiv, 462(5), 507-513. https://doi.org/10.1007/s00428-013-1408-2
  35. Kim, J. Y., Jeong, H. S., Chung, T., Kim, M., Lee, J. H., Jung, W. H., & Koo, J. S. (2017). The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67. Oncotarget, 8(39), 65064-65076. https://doi.org/10.18632/oncotarget.17775
  36. Huang, W., Nebiolo, C., Esbona, K., Hu, R., & Lloyd, R. (2020). Ki67 index and mitotic count: Correlation and variables affecting the accuracy of the quantification in endocrine/neuroendocrine tumors. Annals of diagnostic pathology, 48, 151586. https://doi.org/10.1016/j.anndiagpath.2020.151586
  37. Duregon, E., Bertero, L., Pittaro, A., Soffietti, R., Rudà, R., Trevisan, M., Papotti, M., Ventura, L., Senetta, R., & Cassoni, P. (2016). Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget, 7(16), 21190-21198. https://doi.org/10.18632/oncotarget.8498
  38. Tracht, J., Zhang, K., & Peker, D. (2017). Grading and Prognostication of Neuroendocrine Tumors of the Pancreas: A Comparison Study of Ki67 and PHH3. The journal of histochemistry and cytochemistry, 65(7), 399-405. https://doi.org/10.1369/0022155417708186
  39. Inoue, T., Nakazato, Y., Karube, Y., Maeda, S., Kobayashi, S., & Chida, M. (2018). Mitosis count and number of cancer cells in cases of primary pulmonary adenocarcinoma: Correlations among phosphorylated histone 3, number of cancer cells, nuclear grade, pathologic features and prognosis. Pathology international, 68(3), 159-166. https://doi.org/10.1111/pin.12635
  40. Villani, V., Mahadevan, K. K., Ligorio, M., Fernández-Del Castillo, C., Ting, D. T., Sabbatino, F., Zhang, I., Vangel, M., Ferrone, S., Warshaw, A. L., Lillemoe, K. D., Wargo, J., Deshpande, V., & Ferrone, C. R. (2016). Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Annals of surgical oncology, 23(Suppl 5), 609-617. https://doi.org/10.1245/s10434-016-5171-x
  41. van Steenhoven, J., Kuijer, A., Kornegoor, R., van Leeuwen, G., van Gorp, J., van Dalen, T., & van Diest, P. J. (2020). Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer. Histopathology, 77(4), 579-587. https://doi.org/10.1111/his.14185
  42. Manem, V., Sazonova, O., Gagné, A., Orain, M., Khoshkrood-Mansoori, B., Gaudreault, N., Bossé, Y., & Joubert, P. (2021). Unravelling actionable biology using transcriptomic data to integrate mitotic index and Ki-67 in the management of lung neuroendocrine tumors. Oncotarget, 12(3), 209-220. https://doi.org/10.18632/oncotarget.27874

Downloads

Published

2021-12-01

How to Cite

1.
Zakhartseva LM, Chytaieva HY. Predictive value of morphological features and proliferative markers (mitotic index, Ki-67, PHH3) in bronchopulmonary neuroendocrine tumors. Pathologia [Internet]. 2021Dec.1 [cited 2026May25];18(3):254-62. Available from: https://pat.zsmu.edu.ua/article/view/239530

Issue

Vol. 18 No. 3 (2021)

Section

Original research

License

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Лицензия Creative Commons